The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


New Drug for Peanut Allergy in Toddlers Shown Safe and Effective

Research Report
  ()
The response rate to DBV Technologies SA's drug patch in the recent Phase 3 clinical trial was statistically significant, which bodes well for the company as there is currently no approved therapy for children with this condition.

Good Chance FDA Will Greenlight Solution for Dry Eye Disease

Research Report
  ()
Approval would be positive news for Aldeyra Therapeutics Inc. given the market for the indication is large and underserved, noted a BTIG report.

Small Biomedical Device Co. Is Ready to Take a Big Step Into Success

Contributed Opinion
  ()
After weathering some major setbacks, PetVivo Holdings Inc. is stepping it up. With their new product for osteoarthritis and the team's perseverance, they may soon show themselves as a diamond in the rough.

Approved Drug Shows Promise in Follicular Lymphoma

Research Report
  ()
Comparison of new and previous clinical trial data shows improved efficacy, noted a Wedbush report.

FDA Approval of Drug Could Be on the Way

Research Report
  ()
"We continue to see good overall odds of ultimate approval" despite the current delay, noted an H.C. Wainwright & Co. report, regarding Verrica Pharmaceuticals topical drug for molluscum contagiosum, a viral skin infection.

Important Data for COVID Drug Candidate Due This Month

Research Report
  ()
The "update should be important for determining EDP-235's potential to tap into this large market," noted a ROTH Capital Partners report.

Cancer Patients Have Partial Response With Drug

Research Report
  ()
The developer of this antibody just released the results of its dose evaluation in solid tumors, noted a Wedbush report.

Cancer Targeting Drug Better Tolerated Than Others

Research Report
  ()
A comparison of safety data shows this Phase 3 treatment candidate for liposarcoma differentiates itself from competitors with its superior safety profile, noted an Oppenheimer report.

50% Revenue Growth Expected This Year for Biopharma Co.

Research Report
  ()
The company is pursuing several strategies to boost revenue, including clinical trials to possibly expand the label of one of its approved dermatological drugs, noted a ROTH Capital Partners report.

Target Price on Drug Co. Suggests Possible Huge Returns

Research Report
  ()
Through H2/22, this biopharma intends to keep advancing its psychedelic drug formulations for major depression, noted a ROTH Capital Partners report.

H2/22 Slated to Be Catalyst Rich for Pharma Co.

Research Report
  ()
Streetwise looks over the latest events surrounding Syros Pharmaceuticals after a Roth Capital Partners report shared that its newest updates could bolster the cash position of the firm and, thus, allow it to continue advancing all of its clinical programs.

New Improved Drug Expected to Get FDA Approval Next Month

Research Report
  ()
Greenlighting of its medication for urea cycle disorders is the first of a trio of catalysts anticipated for this U.S. pharma firm in 2022, noted a ROTH Capital Partners report. Streetwise reviews the newest updates in this drug development and the company's stock.

Firm Reports Encouraging Trial Results in Cystinosis

Research Report
  ()
New data from a Wedbush report shows that study patients experienced improvements in visual-motor integration, motor coordination, and visual perception. Streetwise Reports takes a deeper look at Avrobio Inc.

Coverage Launched on Co. in Alzheimer's Drug Space

Research Report
  ()
This biopharma's therapeutic candidates for central nervous system diseases stand out because of their selective and specific mechanism of action, noted a Leede Jones Gable report.

Clinical Catalysts for Biotech's Stock On Track for Mid 2022

Research Report
  ()
Upcoming potential stock-moving events include new data concerning the company's lead therapeutic candidate for age-related eye diseases, noted a ROTH Capital Partners report.

Biopharma Co. to Launch Two Clinical Trials This Year

Research Report
  ()
Success in either program, atopic dermatitis or asthma, "could lead to multiblockbuster sales," noted a ROTH Capital Partners report.

Showing Results: 51 to 75 of 115 Prev Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts